Slide 1: Exchange filing cover letter
May 01, 2023 To, The Manager BSE Limited Listing Department Corporate Relationship Department Floor National Stock Exchange of India Limited 25, P.J. Towers Exchange Plaza, 5th Floor Dalal Street Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Mumbai 400 001. Bandra (East), Mumbai 400 051. Symbol: RPGL
Slide 2: Investors' Presentation FY24
Investors’ Presentation FY24
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses in Infrastructure, Technology, Tyres, Life Sciences, and p
Slide 5: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the Leader in Immunosuppressants
Slide 6: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Text Book Brands Specialty Chronic Life Cycle Management Rheumatology (Existing Products) Vildagliptin Trastuzumab Oncology Azathioprine Azathioprine Adalimumab Teneliglipti
Slide 7: Business Performance
Business Performance LZ An &F2PG Company a RPG LIFE SCIENCES
Slide 8: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixation Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up
Slide 9: FY24 delivers A Strong All-Round Performance
FY24 delivers A Strong All-Round Performance ROCE ROE EPS 14% 26% + 229 bps 31.0% 23.4% Rs. 53.0 New Products Contribution** Mkt Evolution ~30% 13.0%* 110% +5 +118% 7th Fastest growing Company in the Top 75 Companies of IPM* * IQVIA TSA MAT Mar ‘24 ** Launched onwards FY19
Slide 10: Building a Strong-Consistent-Profitable Business
Building a Strong-Consistent-Profitable Business 1 2 3 4 Transforming Driving Building Energizing Product Portfolio Execution Competitiveness Happy Teams 30% >10 x3-4 86% NP Contribution High Impact Projects Happiness Score
Slide 11: Transforming Product Portfolio
1 Transforming Product Portfolio Building Legacy Products into Mega Brands via Smart Life Cycle Management Goal 1 Goal 2 Naprosyn 100 Cr. Immunosuppressants 100 Cr. New Line Extensions 12 Variants 3 New Customer Segments 4 New Customer Segments Building New Chronic/Specialty Franchises Rheumatology
Slide 12: Driving Execution
2 Driving Execution 1 Comprehensive Business Transformation Project 5 ESG Projects Plants Infrastructure Modernization / Capacity 2 Expansion Projects 6 Innovation Projects 3 COGS Reduction Projects 7 Digitalization Projects 4 Products Reengineering Projects Project Charters, Workstreams, Scope, Rev
Slide 13: Building Competitiveness: RPG Serv - A Phygital Innovation
3 Building Competitiveness : RPG Serv - A Phygital Innovation RPG Serv: Anytime Anywhere Doctor Support Initiative 10 versions launched across 10 diverse Customer segments Therapy customization across services to ensure engagement >90K doctors enrolled - Excellent Feedback
Slide 14: Building Competitiveness: Comprehensive Life Cycle Management
3 Building Competitiveness : Comprehensive Life Cycle Management Driving Strategic Brand Building LCM Strategy LCM Application to Legacy Brand - Naprosyn New Strengths New Dosage Forms New Molecule Combinations More New Indications to Follow New Customer Segments New Patient Segments On its way to b
Slide 15: Energizing Happy Teams: Happiness Framework
4 Energizing Happy Teams: Happiness Framework People Initiatives for Building Happy Performance focused Culture I Love My Work RPGLS Heroes I am Growing Outperformance recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum Akanksha Career developmen
Slide 16: Energizing Happy Teams: Happiness Framework
4 Energizing Happy Teams : Happiness Framework People Initiatives for Building Happy Performance focused Culture - Glimpses Hello Happiness Forums: Monthly Townhall for Connect, Recognition and Camaraderie 140+ 100+ Awards Recognitions 1000+ colleagues Celebrated
Slide 17: Energizing Happy Teams: Happiness Framework
4 Energizing Happy Teams : Happiness Framework People Initiatives for Building Happy Performance focused Culture - Glimpses Parivar Tyohar Utsav Shrankhla of Festivals with Families
Slide 18: Energizing Happy Teams: Happiness Framework
4 Energizing Happy Teams : Happiness Framework People Initiatives for Building Happy Performance focused Culture - Glimpses
Slide 19: Financial Performance
Financial Performance LZ An &F2PG Company a RPG LIFE SCIENCES
Slide 20: Full Year FY24: Yet Another Strong Year of Performance
Full Year FY24 : Yet Another Strong Year of Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 582.1 135.4 117.8 512.8 91.7 107.5 23.3% 20.2% 21.0% 17.9% FY23 FY24 FY23 FY24 FY23 FY24 PAT & PAT Margin EPS 53.0 87.7 40.9 67.6 15.1
Slide 21: Q4 FY24 Revenue, EBITDA, PBT, PAT and EPS
(All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 17.7 127.0 22.4 13.8 118.5 17.8 14.0% 17.6% 11.7% 15.0% PAT & PAT Margin EPS 13.2 8.0 6.3 10.4 10.4% 8.7% Figures in circle are Margins
Slide 22: Key Financials Trends
Key Financials Trends (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin 135.4 117.8 582.1 107.5 512.8 89.4 91.7 375.6 389.1 440.2 70.8 73.2 330.2 59.9 53.6 34.4 41.8 15.1 10.4% 15.9% 18.2% 20.3% 21.0% 23.3% 4.6% 11.1% 13.8% 16.6% 17.9% 20.2
Slide 23: Margins: A Trajectory of y-o-y Expansion despite Market Challenges
Margins: A Trajectory of y-o-y Expansion despite Market Challenges EBITDA Margin :10.4% (FY19) to 23.3% (FY24);PBT Margin: 4.6% (FY19) to 20.2% (FY24); PAT Margin: 3.3% (FY19) to 15.1% (FY24) 23.3% EBITDA% 20.3% 21.0% 20.2% 18.2% 16.6% 17.9% PBT% 15.9% 13.8% 15.1% 11.7% 13.2% PAT% 11.1% 11.1% 10.4%
Slide 24: Key Ratios (ROCE, ROE, D/E): A Trajectory of y-o-y uptrend
Key Ratios (ROCE, ROE, D/E) : A Trajectory of y-o-y uptrend ROCE% ROE% Debt/Equity Ratio 31.0% 29.7% 23.4% 28.5% 22.0% 24.9% 20.1% 0.22 18.5% 20.9% 16.4% 0.06 9.7% 0.01 6.7% 0.00 0.00 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 Company continues to remain Deb
Slide 25: FY24: Business Segment-wise Performance
FY24: Business Segment-wise Performance Domestic Formulations contributed 67% to total sales of FY24 390.8 • 15% sales growth driven by both Legacy and New products 340.8 Domestic • Growth consistently higher than the market Business Segments Formulations • New products* contribution improving consi
Slide 26: RPG Life Sciences ICRA Rating Upgradation in FY24
RPG Life Sciences ICRA Rating Upgradation in FY24 Long term rating recently upgraded to A+ from A Short term rating reaffirmed at A1 Outlook on long-term rating has been retained as Stable The rating upgradation factors: • Strong brands in the Indian Pharmaceutical Industry • Steady growth in Top-li
Slide 27: Business Strategy
Business Strategy LZ An &F2PG Company a RPG LIFE SCIENCES
Slide 28: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage - Cardiol
Slide 29: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 30: APIs Business: Business Strategy and Way Forward
APIs Business: Business Strategy and Way Forward • High value, low volume, niche APIs • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus – long-l
Slide 31: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities 30
Slide 32: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved • Modernization cum Capacity Expansion underway
Slide 33: Strong Backend Capabilities
Strong Backend Capabilities Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market • Expertise of eCTD submissions c
Slide 34: Digitalization, Innovation and ESG Highlights
Digitalization, Innovation and ESG Highlights 33
Slide 35: Digitalization Glimpses: Sales & Marketing
Digitalization Glimpses: Sales & Marketing LSAI: Using GenAI for Superior Customer Servicing and impactful Marketing
Slide 36: Roadmap of >20 Initiatives under various stages of Implementation
Roadmap of >20 Initiatives under various stages of Implementation Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access with IRIS/ Retina • Implementation • Operates Pumps • Safe, reliable, Scanner enables of Utility Asse
Slide 37: Innovation Glimpses
Innovation Glimpses Innovation Institutionalization across organization Innovation Goals Innovation Projects Innovation Institutionalization Illustrative Projects Each department to have minimum 1 NapRelief WOMAC Trial : One of the largest project Trials ever conducted in India (10200 patients; 458
Slide 38: ESG Glimpses
ESG Glimpses Initiatives identified post Industry ESG mapping; Good progress Initiatives FY24 • Carbon emission reduction • Energy Efficiency: Energy Efficient pumps ; Leakages rectification of compressed air system; High Efficiency ( chillers/Brine Plant • Water Management: Recycling of STP water;
Slide 39: Awards & Recognitions
Awards & Recognitions LZ An &F2PG Company a RPG LIFE SCIENCES
Slide 40: India's Top Value Creators by Dun & Bradstreet
RPG Life Sciences recognized as India’s Top 500 Value Creators by Dun & Bradstreet 2 EU i). - | dun&bradstreet + pleased to certify Det 25 Evaluation Parameters RPG Life Sciences Limited Duration 2019-2023 Companies from across 52 sectors Vipul Oberoi
Slide 41: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22)
Slide 42: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award
Slide 43: Naprosyn+ bags Brand Champion of the Year Award
New Launch Naprosyn+ bags Brand Champion of the Year Award
Slide 44: Journey Ahead
Journey Ahead LZ An &F2PG Company PG LIFE SCIENCES
Slide 45: Committed to our Transformation Agenda
We are Committed to our Transformation Agenda to continue our upward growth trajectory Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measur
Slide 46: The Journey Ahead: 7 Pillars to Scale-up business
The Journey Ahead: Diligent work on-going on 7 Pillars to “Scale-up” business 7 Pillars Identified 1 2 3 4 5 6 7 State-of-art Targeted Lead Therapy Talent Institutionalized TECHNOLOGY Niche- focus M&As ADJACENT Development enablement PLANTS R&D PIPELINE Spaces /Acquisition • Focused New • Institutio
Slide 47: Thank You
T H A N K Y O U